Emerging drugs for the treatment of light chain amyloidosis
Systemic AL amyloidosis is a protein-misfolding disorder that is characterized by the deposition of insoluble amyloid fibrils derived from kinetically unstable light chains. Achieving a rapid and deep hematologic response is critical for long-term survival.
This review covers the existing and emerging treatment options for systemic AL, divided into anti-plasma cell and fibril-directed therapies. Click here to read more.